Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jenny Scherzer"'
Autor:
Cassidy A. Gutner PhD, Marc van der Valk MD, PhD, Joaquin Portilla MD, Eliette Jeanmaire MD, Leïla Belkhir MD, PhD, Thomas Lutz MD, Rebecca DeMoor MSc, Rekha Trehan BSc, Jenny Scherzer MBA, MSc, Miguel Pascual-Bernáldez PharmB, Mounir Ait-Khaled PhD, Beatriz Hernandez PharmD, PhD, Annemiek de Ruiter MBBS, FRCP, Savita Bakhshi Anand PhD, Emma L. Low PhD, Monica Hadi PhD, Nicola Barnes MA, Nick Sevdalis PhD, Perry Mohammed MBBS, Maggie Czarnogorski MD, MPH
Publikováno v:
Journal of the International Association of Providers of AIDS Care, Vol 23 (2024)
Introduction CARISEL is an implementation–effectiveness “hybrid” study examining the perspectives of people living with HIV-1 (patient study participants [PSPs]) on cabotegravir (CAB) plus rilpivirine (RPV) long-acting (LA) dosed every 2 months
Externí odkaz:
https://doaj.org/article/5d90730f2456430790ded91fab079d5b
Autor:
Cassidy A. Gutner, Laurent Hocqueloux, Celia Jonsson‐Oldenbüttel, Linos Vandekerckhove, Berend J. vanWelzen, Laurence Slama, María Crusells‐Canales, Julián Olalla Sierra, Rebecca DeMoor, Jenny Scherzer, Mounir Ait‐Khaled, Gilda Bontempo, Martin Gill, Natasha Patel, Ronald D'Amico, Kai Hove, Bryan Baugh, Nicola Barnes, Monica Hadi, Emma L. Low, Savita Bakhshi Anand, Alison Hamilton, Harmony P. Garges, Maggie Czarnogorski
Publikováno v:
Journal of the International AIDS Society, Vol 27, Iss 7, Pp n/a-n/a (2024)
Abstract Introduction Cabotegravir plus rilpivirine (CAB + RPV) is the first complete long‐acting (LA) regimen recommended for maintaining HIV‐1 virological suppression. Cabotegravir And Rilpivirine Implementation Study in European Locations (CAR
Externí odkaz:
https://doaj.org/article/cf663c19fbc04c13b44fe74a60666e97
Autor:
Sara Paparini, Vanessa Apea, James Hand, Rachel Phillips, Chloe M Orkin, Jenny Scherzer, Sadna Ullah, Hamzah Z Farooq, Bakita Kasadha, Gill Hilton-Smith, Amber Haley
Publikováno v:
BMJ Open, Vol 13, Iss 7 (2023)
Introduction Cabotegravir and rilpivirine (CAB+RPV long-acting (LA)) is recommended as a treatment for HIV-1 allowing people living with HIV to receive 2 monthly injectable treatment, rather than daily pills. Providing injectable therapy in a system
Externí odkaz:
https://doaj.org/article/0fbdd71ddd2f49abbb54e8c9e24b6e4c
Autor:
Laura Clark, Chitra Karki, Josh Noone, Jenny Scherzer, Martina Bode, Paolo Rizzini, Fabio Vecchio, Laetitia Roustand, Gaelle Nachbaur, Laurent Finkielsztejn, Vasiliki Chounta, Nicolas Van de Velde
Publikováno v:
Population Medicine, Vol 2, Iss October, Pp 1-18 (2020)
Introduction Current antiretroviral therapies (ARTs) require daily oral dosing, which is a challenge for some people living with HIV (PLHIV). Measures of treatment needs that are associated with daily oral ARTs have been identified in studies/intervi
Externí odkaz:
https://doaj.org/article/96fe845d5bfd41f6b4f22622ac99f613
Autor:
Hamzah Z Farooq, Vanessa Apea, Bakita Kasadha, Sadna Ullah, Gill Hilton-Smith, Amber Haley, Jenny Scherzer, James Hand, Sara Paparini, Rachel Phillips, Chloe Orkin
IntroductionCabotegravir and Rilpivirine (CAB+RPV-LA) is recommended as a treatment for HIV-1 allowing people living with HIV to receive two-monthly injectable treatment, rather than daily pills. Providing injectable therapy in a system designed to p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::196ab1bfc329e12fa51fd6e77df8389c
https://doi.org/10.1101/2022.11.30.22282915
https://doi.org/10.1101/2022.11.30.22282915
Autor:
Babatunde Akinwunmi, Nicolas Van de Velde, Paolo Rizzini, Martina Bode, Laurent Finkielsztejn, Laetitia Roustand, Fabio Vecchio, Jenny Scherzer, Daniel Buchenberger, Gaëlle Nachbaur, Vasiliki Chounta
Publikováno v:
Sexually Transmitted Infections. 97:566-573
ObjectivesA novel long-acting regimen (LAR) of cabotegravir and rilpivirine for HIV treatment requires dosing every 2 months instead of daily. We assessed what proportion of people living with HIV and physicians would be interested in trying and offe
Autor:
Paolo Rizzini, Vasiliki Chounta, Fabio Vecchio, Gaëlle Nachbaur, Nicolas Van de Velde, Laetitia Roustand, Josh Noone, Martina Bode, Laura Clark, Chitra Karki, Laurent Finkielsztejn, Jenny Scherzer
Publikováno v:
Population Medicine, Vol 2, Iss October, Pp 1-18 (2020)
Introduction Current antiretroviral therapies (ARTs) require daily oral dosing, which is a challenge for some people living with HIV (PLHIV). Measures of treatment needs that are associated with daily oral ARTs have been identified in studies/intervi
Autor:
Fabio Vecchio, Nicolas Van de Velde, Babatunde Akinwunmi, Laurent Finkielsztejn, Paolo Rizzini, Vasiliki Chounta, Daniel Buchenberger, Gaëlle Nachbaur, Jenny Scherzer, Laetitia Roustand, Martina Bode
Publikováno v:
The European Journal of Public Health
BackgroundThe daily oral dosing requirement for antiretroviral therapy (ART) may be challenging for some people living with HIV (PLWHIV) with comorbid conditions, confidentiality concerns or pill fatigue. We investigated suboptimal adherence from the